

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zylox-Tonbridge Medical Technology Co., Ltd.**

**歸創通橋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

### **VOLUNTARY ANNOUNCEMENT COMPLETION OF PATIENT ENROLLMENT FOR THE ZENFLEX® PERIPHERAL STENT SYSTEM POST-MARKETING CLINICAL TRIAL IN THE EUROPEAN UNION**

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The Company is pleased to announce that ZENFLEX® Peripheral Stent System, independently developed in-house by the Company, completed the enrollment of all 100 patients in the multi-center clinical trial in Germany. The clinical trial is a prospective, multi-center, single arm study to evaluate the effectiveness and safety of ZENFLEX® Peripheral Stent System for adjunctive angioplasty in the treatment of peripheral arterial disease. The study was coordinated by a world-renowned vascular intervention expert, Professor Dierk Scheinert of the University of Leipzig Medical Center, with the participation of vascular intervention clinicians from five hospitals in Europe. This is a post-marketing clinical follow-up trial of ZENFLEX® Peripheral Stent System in the European Union, which is of great significance in proving the clinical value of the product overseas, obtaining EU MDR certification and continuously serving overseas patients.

ZENFLEX® Peripheral Stent System is mainly used for the treatment of peripheral arterial disease (PAD). It has unique open-loop spiral structure and micro-mesh design, with excellent flexibility and radial support for better adherence to the vascular wall. In addition, ZENFLEX® Peripheral Stent System also features a controllable delivery system that enables precise, fast and easy stent release. Since its launch in the European Union in 2017, the product has been recognized and welcomed by local doctors for its innovative product design and high product quality. As of the date of this announcement, the Company has obtained certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area for 8 products and 1 product was granted marketing approval in Brazil.

By order of the board  
**Zylox-Tonbridge Medical Technology Co., Ltd.**  
**Dr. Jonathon Zhong Zhao**  
*Chairman and Executive Director*

Hong Kong, December 20, 2023

*As of the date of this announcement, the board of directors of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive directors.*